Trial document

drksid header


Trial Description

start of 1:1-Block title


Modulation of cerebral somatosensory processing and nociception by treatment with botulinum toxin A in spasticity and dystonia

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The sensory perception of our environment affects large parts of the human brain. It is foundamental for feeling, orientation and decision-making in humans. The brain and the so called cortex are able to process and analyze simultaneously many incoming information.
Today we know that different brain areas communicate like sophisticated networks. Certain diseases, such as spasticity or dystonia, can irritate and disrupt those communication pathways.
The aim of this study is to investigate which brain areas are “malfunctioning” in spasticity and dystonia and in which extend the therapy with botulinum toxin A corrects the "wrong" function.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Intramuscular injection of botulinum toxin A for treatment in specific movement disorders (such as focal dystonia and spastic syndromes in adults and children) is an an effective therapeutic option. Due to active uptake mechanisms located at the presynaptic membrane muscle fibers with high activity are preferred.
Besides motor symptoms, these movement disorders are often associated with unpleasant sensations and pain. In addition recent studies gave clear evidence that in focal dystonia alterations of haptic perception are not limited to the affected body region.
In daily clinical practice, the treatment botulinum toxin improves not only motor symptoms but reduces pain and improves sensory perception. It is known that besides local mechanisms there are also modulations on spinal and cerebral levels.
It remains unclear, how a peripheral motor paralysis leads to persistent functional and structural changes in brain regions that are involved in the processing of somatosensory and nociceptive stimuli.
The aim of this project is to analyze changes in the somatosensory and nociceptive processing in patients with spasticity and focal dystonia under the treatment with botulinum toxin A.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?


end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:


end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003696
  •   2012/04/13
  •   [---]*
  •   yes
  •   Approved
  •   3353-01/12, Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   G24.9 -  Dystonia, unspecified
  •   R25.2 -  Cramp and spasm
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   control group (healthy), structural and functional mri
  •   Dystonia, structural and functional MRI study before and during treatment with botulinum toxin A (0, 3, 12 months)
  •   spasticity, structural and functional MRI study before and during treatment with botulinum toxin A (0, 3, 12 months)
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Other
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Treatment response in group 1 (dystonia) and group 2 (spasticity) after 12 months under treatment with botulinum toxin:
- Dystonia: UDRS (Unified Dystonia Rating Scale), TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale)
- Spasticity: MAS (Mod Ashworth scale), SERS (Spasticity Examination Rating Scale)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Pain reduction (interview with "German Pain Questionnaire") at 0, 3 and 12 months

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2012/04/04
  •   60
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   35   Years
  •   65   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Group 1 (dystonia): evidence of cervical dystonia by a specialist for Neurology, exclusion of other causes for dystonia-like symptomes, right-handed, no other neurological diseases, no pre-medication, MRI compatibility

Group 2 (spasticity): evidence of clinically significant spasticity of the right side of the body following an ischemic infarction by a media, right-handed, no other neurological diseases, no relevant pre-medication, MRI compatibility

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Psychiatric comorbidity, counter indication for MRI

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Klinik für Neurologie FSU Jena
    • Erlanger Allee 101
    • 07747  Jena
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   03641/9323410
    •   03641/9323412
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Merz Pharma GmbH & Co. KGaA Zentrale
    • Eckenheimer Landstraße 100
    • 60318  Frankfurt am Main
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.